Regeneron Pharmaceuticals Files 2024 10-K

TL;DR

Regeneron dropped its 2024 10-K. All systems go.

AI Summary

Regeneron Pharmaceuticals, Inc. filed its 2024 10-K on February 5, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered at 777 Old Saw Mill River Road in Tarrytown, NY, operates within the pharmaceutical preparations industry. Key financial and operational details for the fiscal year are presented in this comprehensive annual report.

Why It Matters

This filing provides investors and the public with a detailed overview of Regeneron's financial performance, strategic initiatives, and risk factors for the 2024 fiscal year, crucial for understanding the company's current standing and future outlook.

Risk Assessment

Risk Level: low — This is a standard annual financial filing (10-K) and does not inherently present new risks beyond those typically associated with a publicly traded pharmaceutical company.

Key Numbers

• 2024 — Fiscal Year (Reporting period for the 10-K)
• 1231 — Fiscal Year End (Indicates the end date of the reporting period)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Filer
• 0000872589 (company) — Central Index Key
• 20241231 (date) — Conformed Period of Report
• 20250205 (date) — Filed as of Date
• 777 OLD SAW MILL RIVER ROAD (address) — Business Address
• TARRYTOWN (location) — City
• NY (location) — State
• 10591 (postal_code) — ZIP Code
• 9148477000 (phone_number) — Business Phone
• KathrynGuariniPh.D.Membe (person) — Mentioned in filing context

FAQ

Key Financial Figures

• $6 million — mber 31, 2023 and 2022 is approximately $6 million and $34 million, respectively, of net p
• $34 m — nd 2022 is approximately $6 million and $34 million, respectively, of net product sal

Filing Documents

• regn-20241231.htm (10-K) — 3114KB
• regn-ex_41x12312024x10k.htm (EX-4.1) — 16KB
• regn-ex_1081x12312024x10k.htm (EX-10.8 1) — 134KB
• regn-ex_191x12312024x10k.htm (EX-19.1) — 82KB
• regn-ex_211x12312024x10k.htm (EX-21.1) — 22KB
• regn-ex_231x12312024x10k.htm (EX-23.1) — 3KB
• regn-ex_311x12312024x10k.htm (EX-31.1) — 12KB
• regn-ex_312x12312024x10k.htm (EX-31.2) — 12KB
• regn-ex_32x12312024x10k.htm (EX-32) — 7KB
• image_0a.jpg (GRAPHIC) — 10KB
• regn-20241231_g1.jpg (GRAPHIC) — 108KB
• 0001804220-25-000011.txt ( ) — 14061KB
• regn-20241231.xsd (EX-101.SCH) — 82KB
• regn-20241231_cal.xml (EX-101.CAL) — 113KB
• regn-20241231_def.xml (EX-101.DEF) — 459KB
• regn-20241231_lab.xml (EX-101.LAB) — 939KB
• regn-20241231_pre.xml (EX-101.PRE) — 711KB
• regn-20241231_htm.xml (XML) — 2137KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 34 Item 1B. Unresolved Staff Comments 67 Item 1C. Cybersecurity 67 Item 2.

Properties

Properties 68 Item 3.

Legal Proceedings

Legal Proceedings 68 Item 4. Mine Safety Disclosures 68 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 69 Item 6. [Reserved] 70 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 70 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 84 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 85 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 85 Item 9A.

Controls and Procedures

Controls and Procedures 85 Item 9B. Other Information 86 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 86 PART III Item 10. Directors, Executive Officers and Corporate Governance 86 Item 11.

Executive Compensation

Executive Compensation 86 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 86 Item 13. Certain Relationships and Related Transactions, and Director Independence 86 Item 14. Principal Accountant Fees and Services 86 PART IV Item 15. Exhibits and Financial Statement Schedules 87 Item 16. Form 10-K Summary 91 SIGNATURE PAGE 92 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD ," "Inmazeb ," "Libtayo ," "Ordspono ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," "Veloci-Bi ," "VelociGene ," "VelociHum ," "VelociMab ," "VelocImmune ," "VelociMouse ," "VelociSuite ," "VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products. Table of Contents PART I

Business

Item 1. Business This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others: the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation those discussed or referenced in this report, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, including without limitation those discussed or referenced in this report; the e

View Full Filing

View this 10-K filing on SEC EDGAR